NewsBenzingaInnate Pharma: ricavi dei primi 9 mesi a 3,4 milioni di euro contro 2,3 milioni di euro su base annua; cassa a 96,8 milioni di euro; il CFO Frédéric Lombard lascerà l’incarico il 31 dicembre Innate Pharma: ricavi dei primi 9 mesi a 3,4 milioni di euro contro 2,3 milioni di euro su base annua; cassa a 96,8 milioni di euro; il CFO Frédéric Lombard lascerà l’incarico il 31 dicembre Benzinga 2026.11.05 07:52 (GMT+0) Open on Benzinga Other news Qualcomm Shares Lose Signal: What’s Going On? BTIG Downgrades Paycom Software to Neutral ProFrac Holding Q3 Sales $511.100M Miss $548.385M Estimate Gildan Activewear Q3 Adj. EPS $1.54 Misses $1.60 Estimate, Sales $1.467B Miss $1.633B Estimate Gildan Activewear Lowers FY2026 Adj EPS Guidance from $4.65-$4.75 to $3.70-$3.80 vs $4.64 Est; Lowers FY2026 Sales Guidance from $6.000B to $5.400B-$5.500B vs $5.988B Est Toyota Motor Raises FY2027 GAAP EPS Guidance from $17.08 to $18.84 vs $21.80 Est; Lowers FY2027 Sales Guidance from $338.850B to $336.087B vs $337.600B Est
Gildan Activewear Lowers FY2026 Adj EPS Guidance from $4.65-$4.75 to $3.70-$3.80 vs $4.64 Est; Lowers FY2026 Sales Guidance from $6.000B to $5.400B-$5.500B vs $5.988B Est
Toyota Motor Raises FY2027 GAAP EPS Guidance from $17.08 to $18.84 vs $21.80 Est; Lowers FY2027 Sales Guidance from $338.850B to $336.087B vs $337.600B Est
